Opportunity Information: Apply for PA 12 196
Apply for PA 12 196
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Innovative Health Information Technology for Broad Adoption by Healthcare Systems and Consumers (SBIR) (R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.399 Cancer Control 93.879 Medical Library Assistance.
- This funding opportunity was created on Jun 5, 2012 and posted on Jun 5, 2012.
- Applicants must submit their applications by Jan 7, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled Innovative Health Information Technology for Broad Adoption by Healthcare Systems and Consumers (SBIR) (R44) is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant solicitation focused on moving proven, evidence-based health information technology products closer to real-world, large-scale use. The core aim is not just to build a prototype, but to support small businesses in taking health IT innovations through the harder, later-stage steps needed for commercialization and broad dissemination across healthcare systems and consumer markets. In practice, this means the program is oriented toward solutions that can be adopted widely, fit into real clinical and consumer workflows, and show credible potential to improve health outcomes at scale.
This FOA specifically invites proposals from eligible small business concerns that are developing and disseminating health IT products that address at least one of three priority goals: preventing cancer or reducing cancer risk, improving patient-provider communication, and/or improving disease outcomes. The emphasis on evidence-based products signals that NIH is looking for solutions grounded in research and measurable performance, rather than purely conceptual ideas. The scope is tied strongly to cancer-related public health needs, as reflected in the associated CFDA listings covering cancer prevention, detection/diagnosis, treatment, and control, along with a medical library assistance category that aligns with information access and dissemination.
Eligibility is limited to small businesses, and the mechanism is SBIR Phase II (R44) with the option for Fast Track (combined Phase I/Phase II) submissions. A key requirement is that the applicant must either already have a prior Phase I SBIR award (which establishes feasibility and early proof-of-concept) or apply through the Fast Track pathway under this announcement. This structure makes the opportunity explicitly transitional: it is designed for projects that have already cleared early technical risk and are ready to demonstrate effectiveness, refine implementation, and prepare for market entry and scale.
A central feature of this FOA is its commercialization focus. Phase II and Fast Track applications must include a Commercialization Plan, and that plan is not treated as a formality. Applicants are expected to lay out how the product will reach broad adoption, including target users and customers, market strategy, competitive positioning, regulatory or compliance considerations where applicable, reimbursement strategy if relevant, pricing assumptions, deployment and support models, and milestones that show a credible path from development to sustained use. The announcement also highlights NIH's interest in partnerships between small businesses and larger businesses or health-related organizations that have established capacity to commercialize, distribute, implement, or disseminate health IT products. In other words, NIH is encouraging applicants to build real channels to adoption, such as partnerships with health systems, payers, professional associations, patient advocacy organizations, or large healthcare technology firms that can accelerate scale-up beyond what a small business could typically do alone.
From an administrative standpoint, this is a discretionary grant opportunity issued by NIH. It does not require cost sharing or matching, which lowers the barrier for small businesses that may not have substantial non-federal funds to contribute. The opportunity was originally posted on June 5, 2012, and the final closing date listed is January 7, 2015, with an archive date of February 7, 2015. While that means this particular announcement is historical and no longer accepting applications, the summary is still useful as a model for what NIH has sought in health IT-focused SBIR commercialization awards: evidence-based solutions, clear clinical or consumer impact (especially around cancer risk and outcomes), and a strong, well-supported plan for scaling through partnerships and market-ready dissemination.
For applicants or researchers trying to locate the full archived announcement and details, the NIH grants guide link associated with the FOA is provided (PA 12-196). The contact listed for access or linking issues is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV, which is intended for technical difficulties accessing the posting rather than scientific or programmatic questions.
Frequently Asked Questions (FAQs)
What is the title of this NIH SBIR funding opportunity?
The funding opportunity is titled Innovative Health Information Technology for Broad Adoption by Healthcare Systems and Consumers (SBIR) (R44).
Which federal agency sponsors this opportunity?
This opportunity is sponsored by the National Institutes of Health (NIH).
What type of program is this (SBIR/STTR, and which phase)?
This is a Small Business Innovation Research (SBIR) opportunity using the Phase II (R44) mechanism, with an option to apply via a Fast Track pathway (combined Phase I/Phase II).
What is the main purpose or focus of this FOA?
The FOA is focused on moving proven, evidence-based health information technology (health IT) products closer to real-world, large-scale use. The emphasis is on later-stage work needed for commercialization and broad dissemination across healthcare systems and consumer markets, not simply building an initial prototype.
What kinds of products or solutions is NIH looking for under this FOA?
NIH is looking for evidence-based health IT products that can be adopted widely, fit into real clinical and consumer workflows, and show credible potential to improve health outcomes at scale.
What priority goals must an application address?
Proposals must address at least one of these three priority goals:
- Preventing cancer or reducing cancer risk
- Improving patient-provider communication
- Improving disease outcomes
Is this opportunity tied specifically to cancer-related needs?
Yes. The scope is strongly tied to cancer-related public health needs, reflected in associated categories covering cancer prevention, detection/diagnosis, treatment, and control. It also references a medical library assistance category aligning with information access and dissemination.
Who is eligible to apply?
Eligibility is limited to eligible small business concerns.
Does an applicant need a prior SBIR Phase I award to apply?
Yes. A key requirement is that the applicant must either:
- Already have a prior SBIR Phase I award, or
- Apply through the Fast Track pathway under this announcement.
What does the Fast Track option mean in this FOA?
The Fast Track option allows submission for a combined Phase I/Phase II pathway under the announcement, rather than applying to Phase II only after completing Phase I separately.
What stage of development is this FOA designed to support?
This FOA is positioned as a transitional, later-stage opportunity. It is designed for projects that have already cleared early technical risk and are ready to demonstrate effectiveness, refine implementation, and prepare for market entry and scale.
Is a Commercialization Plan required?
Yes. Phase II and Fast Track applications must include a Commercialization Plan, and the FOA emphasizes that it is a central, substantive component of the application rather than a formality.
What does NIH expect a Commercialization Plan to cover under this FOA?
Based on the FOA summary, the Commercialization Plan is expected to address how the product will achieve broad adoption, including:
- Target users and customers
- Market strategy
- Competitive positioning
- Regulatory or compliance considerations (where applicable)
- Reimbursement strategy (if relevant)
- Pricing assumptions
- Deployment and support models
- Milestones showing a credible path from development to sustained use
Does NIH encourage partnerships as part of the approach to commercialization?
Yes. The FOA highlights NIH interest in partnerships between small businesses and larger businesses or health-related organizations with established capacity to commercialize, distribute, implement, or disseminate health IT products.
What types of partners are suggested as helpful for scale-up?
The summary notes channels that can accelerate adoption beyond what a small business can typically do alone, such as partnerships with:
- Health systems
- Payers
- Professional associations
- Patient advocacy organizations
- Large healthcare technology firms
Is cost sharing or matching required?
No. The opportunity does not require cost sharing or matching.
Is this a discretionary grant opportunity?
Yes. It is described as a discretionary grant opportunity issued by NIH.
Is this funding opportunity still accepting applications?
No. The opportunity is historical and is no longer accepting applications.
What were the key dates for this FOA?
The summary lists these dates:
- Original posting date: June 5, 2012
- Final closing date: January 7, 2015
- Archive date: February 7, 2015
Where can someone look up the archived NIH announcement?
The archived NIH Grants Guide posting is associated with PA 12-196.
Who should be contacted for technical issues accessing or linking to the FOA posting?
The contact listed for access or linking issues is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Is the listed contact intended for scientific or programmatic questions about the FOA?
No. The summary specifies that this contact is intended for technical difficulties accessing the posting, not for scientific or programmatic questions.
What is the key theme that distinguishes this FOA from earlier-stage R&D solicitations?
The distinguishing theme is that the FOA prioritizes moving beyond early feasibility and prototypes toward market-ready dissemination, workflow fit, and credible large-scale adoption, supported by a detailed commercialization approach and, where appropriate, strategic partnerships.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: National Cyber Security Awareness
Previous opportunity: Runaway and Homeless Youth Training and Technical Assistance Center
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 196
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 196) also looked into and applied for these:
| Funding Opportunity |
|---|
| Community Clinical Oncology Program Groups (U10) Apply for RFA CA 12 007 Funding Number: RFA CA 12 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Minority Based Community Clinical Oncology Program Groups (U10) Apply for RFA CA 12 008 Funding Number: RFA CA 12 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIMH Career Transition Award for Tenure Track and Tenured Intramural Investigators (K22) Apply for PAR 12 201 Funding Number: PAR 12 201 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Education Grants for Statistical and Computational Training in the Genetics of Addiction (R25) Apply for PAR 12 199 Funding Number: PAR 12 199 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| U.S. India Bilateral Collaborative Research Partnerships (CRP) on the Prevention of HIV/AIDS and Co morbidities (R21) Apply for RFA AI 12 033 Funding Number: RFA AI 12 033 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Establish Sharing of Human Brain Image Data Relevant to Drug Addiction (Admin Supp) Apply for PAR 12 204 Funding Number: PAR 12 204 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Advancing Exceptional Research on HIV/AIDS (R01) Apply for RFA DA 13 008 Funding Number: RFA DA 13 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identifying Non coding RNA Targets for Early Detection of Cancer (R01) Apply for PA 12 213 Funding Number: PA 12 213 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identifying Non coding RNA Targets for Early Detection of Cancer (R21) Apply for PA 12 214 Funding Number: PA 12 214 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R21) Apply for PA 12 220 Funding Number: PA 12 220 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R01) Apply for PA 12 221 Funding Number: PA 12 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cohort Studies of HIV/AIDS and Substance Use (U01) Apply for PAR 12 222 Funding Number: PAR 12 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R01) Apply for RFA MH 13 090 Funding Number: RFA MH 13 090 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R21) Apply for RFA MH 13 091 Funding Number: RFA MH 13 091 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R34) Apply for RFA MH 13 092 Funding Number: RFA MH 13 092 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Addressing Needs of Informal Caregivers of Individuals with Alzheimers Disease in the Context of Sociodemographic Factors (R01) Apply for RFA NR 13 001 Funding Number: RFA NR 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R01) Apply for PAR 12 228 Funding Number: PAR 12 228 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R21) Apply for PAR 12 229 Funding Number: PAR 12 229 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Translational Research on Interventions for Adolescents in the Legal System TRIALS (U01) Apply for RFA DA 13 009 Funding Number: RFA DA 13 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PAR 12 238 Funding Number: PAR 12 238 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 196", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.